BRAINSWAY LTD-ADR
BWAYNASDAQTrading Snapshot
- Day Range
- $11.59 – $12.00
- 52-Week Range
- $2,391.00 – $5,123.00
- Volume (shares)
- 121,732
- Avg Volume (shares)
- —
- Shares Outstanding
- 40.3M
- Next Earnings
- 2026-11-18
Fundamentals Snapshot
- Annual Revenue
- $52M
- Last Q Revenue
- $17M
- P/E Ratio
- 52.1
- P/S Ratio
- 9.3x
- EPS (TTM)
- $0.23
- Dividend Yield
- —
- Dilution (1yr)
- −44.3%
BRAINSWAY LTD-ADR
BWAY
StockOtter · stockotter.spaceAbout BRAINSWAY LTD-ADR
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental heal
BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives
BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announ
BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group
Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry Treatments Partnership with Established Southern California Behavioral He
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announ
HWG Holdings LP Buys New Stake in Brainsway Ltd. Sponsored ADR $BWAY
HWG Holdings LP purchased a new stake in Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased
Head to Head Survey: CapsoVision (NASDAQ:CV) vs. Brainsway (NASDAQ:BWAY)
CapsoVision (NASDAQ: CV - Get Free Report) and Brainsway (NASDAQ: BWAY - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the streng